Advertisement

Esophagus

, Volume 16, Issue 2, pp 141–146 | Cite as

Construction of a risk model for the development of metachronous squamous cell carcinoma after endoscopic resection of esopahageal squamous cell carcinoma

  • Yuji UrabeEmail author
  • Kenichi Kagemoto
  • Koki Nakamura
  • Takeshi Mizumoto
  • Yoji Sanomura
  • Shiro Oka
  • Hidenori Ochi
  • Shinji Tanaka
  • Kazuaki Chayama
Original Article
  • 62 Downloads

Abstract

Background

Previously, we identified that rs1229984 in ADH1B, rs671 in ALDH2, and smoking status were independently associated with the risk of developing metachronous squamous cell carcinoma (SCC) after endoscopic resection (ER) for esophageal SCC (ESCC). However, this analysis included cases with short-term follow-up. In the present study, we investigated the environmental and genetic factors associated with developing metachronous SCC using long-term follow-up observation after ER for ESCC.

Methods

One hundred and thirty ESCC patients who underwent treatment with ER were followed up using endoscopy for ≥ 30 months. We investigated the incidence of, and genetic/environmental factors associated with, metachronous SCC development after ER for ESCC. We also analyzed the potential risk factors for multiple metachronous SCC development using Cox’s proportional hazards model. Moreover, we constructed a risk model for the development of metachronous SCC after ER for ESCC.

Results

Male, rs1229984, rs671, alcohol consumption (> 20 g/day), smoking, and multiple Lugol-voiding lesions (LVLs) significantly affected the incidence of multiple metachronous SCCs. Multiple Cox proportional analysis revealed that rs1229984, rs671, alcohol consumption, smoking, and multiple LVLs were independently associated with the risk of developing metachronous SCC. Patients who had ≤ 2 risk factors did not develop metachronous SCC, and the risk of developing metachronous SCC in patients with ≥ 3 risk factors was significantly higher than in patients with ≤ 2 risk factors.

Conclusion

The risk model using these 5 genetic and environmental factors is useful as an indication for multiple metachronous development in ESCC patients.

Keywords

Esophageal squamous cell carcinoma Metachronous multiple SCC Risk model 

Notes

Acknowledgments

We would like to thank all the patients and members of the Hiroshima Liver Study Group in Japan, who donated their DNA for this study. We also thank Sakamiya and Izumoto, RIKEN, and the technical staff of the Laboratory for Genotyping Development, Center for Genomic Medicine, RIKEN for their technical support.

Compliance with ethical standards

Ethical Statement

The identity of the patients has been protected by linkable anonymizing.

Conflict of interest

All authors report no conflicts of interest associated with this manuscript.

Informed consent

All study participants provided informed consent, and the study design was approved by the Hiroshima University Human Genome ethics review board.

Supplementary material

10388_2018_643_MOESM1_ESM.pdf (588 kb)
Supplementary material 1 (PDF 588 kb)
10388_2018_643_MOESM2_ESM.xlsx (14 kb)
Supplementary material 2 (XLSX 13 kb)

References

  1. 1.
    Kim JH, Chung HS, Youn YH, et al. Treatment outcomes of 70 cases of early esophageal carcinoma: 12 years of experience. Dis Esophagus. 2007;20:297–300.CrossRefGoogle Scholar
  2. 2.
    Cui R, Kamatani Y, Takahashi A, et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology. 2009;137:1768–75.CrossRefGoogle Scholar
  3. 3.
    Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA. 1990;87:9958–61.CrossRefGoogle Scholar
  4. 4.
    Casson AG, Tammemagi M, Eskandarian S, Redston M. McLaughlin, J, Ozcelik, H.p53 alterations in oesophageal cancer: association with clinicopathological fea- tures, risk factors, and survival. Mol Pathol. 1998;51:71–9.CrossRefGoogle Scholar
  5. 5.
    Beroukhim R, Mermel CH, Porter D, Wei G, Raychaud-huri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905.CrossRefGoogle Scholar
  6. 6.
    Sawada G, Niida A, Uchi R, et al. Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology. 2016;150(5):1171–82.CrossRefGoogle Scholar
  7. 7.
    Wang GQ, Abnet CC, Shen Q, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54:187–92.CrossRefGoogle Scholar
  8. 8.
    Enzinger PC, Mayer RJ. Medical progress—esophageal cancer. N Engl J Med. 2003;349:2241–52.CrossRefGoogle Scholar
  9. 9.
    Cui R, Kamatani Y, Takahashi A, et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology. 2009;137:1768–75.CrossRefGoogle Scholar
  10. 10.
    Kagemoto K, Urabe Y, Miwata T, et al. ADH1B and ALDH2 are associated with metachronous SCC after endoscopic submucosal dissection of esophageal squamous cell carcinoma. Cancer Med. 2016;5:1397–404.CrossRefGoogle Scholar
  11. 11.
    Japanese Society for Cancer of the Esophagus. General rules for clinical and pathological studies on cancer of esophagus. 3rd ed. Tokyo: Kanehara & Co. Ltd; 2012.Google Scholar
  12. 12.
    Muto M, Hitomi Y, Ohtsu A, et al. Association of aldehyde dehydrogenase 2 gene polymorphism with multiple oesophageal dysplasia in head and neck cancer patients. Gut. 2000;47:256–61.CrossRefGoogle Scholar
  13. 13.
    Shimoda T. Japanese classification of esophageal cancer, the 10th edition-pathological part. Nihon Rinsho. 2011;69:109–20.Google Scholar
  14. 14.
    Yokoyama A, Katada C, Yokoyama T, et al. Alcohol abstinence and risk assessment for second esophageal cancer in Japanese men after mucosectomy for early esophageal cancer. PLoS One. 2017;12(4):e0175182.CrossRefGoogle Scholar
  15. 15.
    Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7:599–612.CrossRefGoogle Scholar
  16. 16.
    Uebelacker M, Lachenmeier DW. Quantitative determination of acetaldehyde in foods using automated digestion with simulated gastric fluid followed by headspace gas chromatography. J Autom Methods Manag Chem. 2011;2011:907317.CrossRefGoogle Scholar
  17. 17.
    Salaspuro VJ, Hietala JM, Marvola ML, et al. Eliminating carcinogenic acetaldehyde by cysteine from saliva during smoking. Cancer Epidemiol Biomark Prev. 2006;15:146–9.CrossRefGoogle Scholar
  18. 18.
    Wang M, McIntee EJ, Cheng G, Villalta PW, Hecht SS, et al. Identification of DNA adducts of acetaldehyde. Chem Res Toxicol. 2000;13:1149–57.CrossRefGoogle Scholar
  19. 19.
    Fang JL, Vaca CE. Development of a 32P-postlabelling method for the analysis of adducts arising through the reaction of acetaldehyde with 2’-deoxyguanosine-3′-monophosphate and DNA. Carcinogenesis. 1995;16:2177–85.CrossRefGoogle Scholar
  20. 20.
    Hecht SS, McIntee EJ, Wang M. New DNA adducts of crotonaldehyde and acetaldehyde. Toxicology. 2001;166:31–6.CrossRefGoogle Scholar
  21. 21.
    Balbo S, Hashibe M, Gundy S, et al. N2-ethyldeoxyguanosine as a potential biomarker for assessing effects of alcohol consumption on DNA. Cancer Epidemiol Biomarkers Prev. 2008;17:3026–32.CrossRefGoogle Scholar
  22. 22.
    Chen L, Wang M, Villalta PW, et al. Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation. Chem Res Toxicol. 2007;20:108–13.CrossRefGoogle Scholar
  23. 23.
    Yukawa Y, Muto M, Hori K, et al. Combination of ADH1B*2/ALDH2*2 polymorphisms alters acetaldehyde-derived DNA damage in the blood of Japanese alcoholics. Cancer Sci. 2012;103:1651–5.CrossRefGoogle Scholar
  24. 24.
    Yukawa Y, Ohashi S, Amanuma Y, et al. Impairment of aldehyde dehydrogenase 2 increases accumulation of acetaldehyde-derived DNA damage in the esophagus after ethanol ingestion. Am J Cancer Res. 2014;4:279–84.Google Scholar
  25. 25.
    Matsuda T, Terashima I, Matsumoto Y, et al. Effective utilization of N2-ethyl-2-deoxyguanosine triphosphate during DNA synthesis catalyzed by mammalian replicative DNApolymerases. Biochemistry. 1999;38:929–35.CrossRefGoogle Scholar
  26. 26.
    Yin SJ, Bosron WF, Li TK, et al. Polymorphism of human liver alcohol dehydrogenase: identification of ADH2 2-1 and ADH2 2-2 phenotypes in the Japanese by isoelectric focusing. Biochem Genet. 1984;22:169–80.CrossRefGoogle Scholar
  27. 27.
    Shimizu Y, Tukagoshi H, Fujita M, et al. Metachronous squamous-cell carcinoma of the esophagus arising after endoscopic mucosal resection. Gastrointest Endosc. 2001;54:190–4.CrossRefGoogle Scholar
  28. 28.
    Katada C, Muto M, Tanabe S, et al. Surveillance after endoscopic mucosal resection or endoscopic submucosal dissection for esophageal squamous cell carcinoma. Dig Endosc. 2013;25(Suppl 1):39–43.CrossRefGoogle Scholar
  29. 29.
    Yokoyama A, Katada C, Yokoyama T, et al. Alcohol abstinence and risk assessment for second esophageal cancer in Japanese men after mucosectomy for early esophageal cancer. PLoS One. 2017;12:e0175182.CrossRefGoogle Scholar
  30. 30.
    Kurokawa Y, Muto M, Minashi K, et al. A phase II trial of combined treatment of endoscopic mucosal resection and chemoradiotherapy for clinical stage I esophageal carcinoma: Japan Clinical Oncology Group Study JCOG0508. Jpn J Clin Oncol. 2009;39:686–9.CrossRefGoogle Scholar

Copyright information

© The Japan Esophageal Society and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Regeneration and Medicine Center for Translational and Clinical ResearchHiroshima University HospitalHiroshimaJapan
  2. 2.Department of Gastroenterology and MetabolismHiroshima University HospitalHiroshimaJapan
  3. 3.Department of EndoscopyHiroshima University HospitalHiroshimaJapan

Personalised recommendations